New inhaled drug hopes to heal lungs in ventilator patients
NCT ID NCT07558538
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a single inhaled dose of a lab-made protein (Rh-KGF-2) in 24 adults with moderate to severe ARDS who are on ventilators. The goal is to see if the drug is safe and tolerable, and to find the right dose. Participants are split into three dose groups, with most getting the drug and a few receiving standard care alone. The study lasts 28 days and tracks side effects, oxygen levels, and lung recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant human keratinocyte growth factor-2 (Rh-KGF-2) inhaled powder
- What this could lead to
- If it works, this could point toward a new treatment to help repair lung damage in ARDS patients on ventilators.
- What could go wrong
- This is a very early, small trial (24 people) testing only a single dose. It primarily checks safety, not effectiveness, and the drug may cause airway spasms or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ShanghaiZhongshan
RECRUITINGShanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cell infusion aims to free ARDS patients from ventilators
- New ventilation strategy aims to reduce lung damage in severe pneumonia
- Scientists build a biobank to decode ARDS and personalize treatment
- Scientists hunt for hidden ARDS subtypes to crack deadly lung failure
- Simple chest squeeze may replace High-Tech ventilator settings
- Lab study hopes to unlock ARDS treatment using patient blood cells